{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T23:44:18Z","timestamp":1776815058395,"version":"3.51.2"},"reference-count":42,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"unspecified","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["CRT114316"],"award-info":[{"award-number":["CRT114316"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["G0901226"],"award-info":[{"award-number":["G0901226"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Resp Res"],"accepted":{"date-parts":[[2026,1,4]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive fibrotic lung disease. Prospective study of fibrosis in the lung endpoints (PROFILE) was a prospective, observational cohort study designed to better define the natural history of IPF, understand disease biology and identify biomarkers to support disease management and enhance clinical trial design.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Individuals with an incident diagnosis of IPF were recruited between 2010 and 2017 across two co-ordinating centres in the UK. Demographics, clinical measurements and blood samples were obtained at baseline, and 1, 3, 6, 12, 24 and 36 months. Disease progression events were defined as death or relative forced vital capacity (FVC) decline &gt;10% at 12 months. Survival estimates were modelled using Cox proportional hazards; longitudinal lung function decline was estimated using mixed effect models, specified with restricted cubic splines, a random intercept for participant and random effect for study visit. All models were adjusted for baseline age, sex and continuous baseline percent predicted FVC (ppFVC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 632 participants were recruited, 77.1% were male, and mean age at enrolment was 70.4 years (SD 8.4). Mean baseline ppFVC was 79.5% (SD 19.2), and mean percent predicted DL\n                      <jats:sub>CO<\/jats:sub>\n                      (ppDL\n                      <jats:sub>CO<\/jats:sub>\n                      ) was 45.7% (SD 15.1). A total of 304 (48.1%) participants met disease progression criteria at 1 year. Median survival was 3.7 years (95%CI 3.3 to 4.0). More severe baseline physiology, 12-month relative lung function decline \u226510%, older age and short telomeres were independent risk factors for mortality. Twelve-month estimated change in ppFVC was \u22125.28% (95% CI \u22126.34 to \u22124.22) with an average FVC decline of 186.9\u2009mL (95% CI \u2212225.4 to \u2212148.5); 12-month estimated change in ppDL\n                      <jats:sub>CO<\/jats:sub>\n                      was \u22123.35% (95% CI \u22124.30 to \u22122.40).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The PROFILE cohort confirms that untreated IPF is inexorably progressive and inevitably fatal with a poor median survival from diagnosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjresp-2025-003763","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T15:10:12Z","timestamp":1769613012000},"page":"e003763","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Prospective study of fibrosis in the lung endpoints (PROFILE): characteristics of an incident cohort of patients with idiopathic pulmonary fibrosis"],"prefix":"10.1136","volume":"13","author":[{"given":"Toby M","family":"Maher","sequence":"first","affiliation":[{"name":"USC Keck School of Medicine, Los Angeles, California, USA"},{"name":"Margaret Turner Warwick Centre for Fibrosing Lung Disease, Imperial College London National Heart and Lung Institute, London, England, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7929-2119","authenticated-orcid":false,"given":"Gisli R","family":"Jenkins","sequence":"additional","affiliation":[{"name":"Margaret Turner Warwick Centre for Fibrosing Lung Disease, Imperial College London National Heart and Lung Institute, London, England, UK"},{"name":"Respiratory Theme, National Institute for Health Research Imperial Biomedical Research Centre, London, England, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gauri","family":"Saini","sequence":"additional","affiliation":[{"name":"Royal Papworth Hospital, Cambridge, England, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Braybrooke","sequence":"additional","affiliation":[{"name":"Respiratory Medicine, Clinical Sciences Building, Nottingham City Hospital, Hucknall Road, University of Nottingham, Nottingham, England, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9837-2763","authenticated-orcid":false,"given":"Simon R","family":"Johnson","sequence":"additional","affiliation":[{"name":"Centre for Respiratory Research and NIHR Biomedical Research Centre, School of Medicine, University of Nottingham, Nottingham, England, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Chua","sequence":"additional","affiliation":[{"name":"Royal Brompton Hospital, London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pauline T","family":"Lukey","sequence":"additional","affiliation":[{"name":"Target to Treatment Consulting Ltd, Stevenage Bioscience Catalyst, Stevenage, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliet K","family":"Simpson","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Research & Development Limited, London, England, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard J","family":"Allen","sequence":"additional","affiliation":[{"name":"NIHR Leicester Biomedical Research Centre, Leicester, England, UK"},{"name":"Genetic Epidemiology Group, Department of Health Sciences, University of Leicester, Leicester, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4951-1867","authenticated-orcid":false,"given":"Louise V","family":"Wain","sequence":"additional","affiliation":[{"name":"NIHR Leicester Biomedical Research Centre, Leicester, England, UK"},{"name":"Genetic Epidemiology Group, Department of Health Sciences, University of Leicester, Leicester, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William A","family":"Fahy","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Research & Development Limited, London, England, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1301-8800","authenticated-orcid":false,"given":"Philip L","family":"Molyneaux","sequence":"additional","affiliation":[{"name":"Margaret Turner Warwick Centre for Fibrosing Lung Disease, Imperial College London National Heart and Lung Institute, London, England, UK"},{"name":"Respiratory Theme, National Institute for Health Research Imperial Biomedical Research Centre, London, England, UK"},{"name":"Royal Brompton Hospital, London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1340-2688","authenticated-orcid":false,"given":"Iain","family":"Stewart","sequence":"additional","affiliation":[{"name":"Margaret Turner Warwick Centre for Fibrosing Lung Disease, Imperial College London National Heart and Lung Institute, London, England, UK"},{"name":"Respiratory Theme, National Institute for Health Research Imperial Biomedical Research Centre, London, England, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"key":"2026012807100763000_13.1.e003763.1","doi-asserted-by":"publisher","DOI":"10.1001\/JAMA.2024.3669"},{"key":"2026012807100763000_13.1.e003763.2","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00591-2021","article-title":"Mortality and survival in idiopathic pulmonary fibrosis: a systematic review and meta-analysis","volume":"8","author":"Zheng","year":"2022","journal-title":"ERJ Open Res"},{"key":"2026012807100763000_13.1.e003763.3","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201006-0894CI"},{"key":"2026012807100763000_13.1.e003763.4","first-page":"28","article-title":"Challenges in IPF diagnosis, current management and future perspectives","volume":"32 Suppl 1","author":"Wells","year":"2015","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2026012807100763000_13.1.e003763.5","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202312-2213SO"},{"key":"2026012807100763000_13.1.e003763.6","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.5827"},{"key":"2026012807100763000_13.1.e003763.7","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S2213-2600(13)70045-6","article-title":"Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study","volume":"1","author":"Noth","year":"2013","journal-title":"Lancet Respir Med"},{"key":"2026012807100763000_13.1.e003763.8","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201505-1010OC"},{"key":"2026012807100763000_13.1.e003763.9","doi-asserted-by":"crossref","DOI":"10.1186\/s12890-022-02281-8","article-title":"Design and rationale for the prospective treatment efficacy in IPF using genotype for NAC selection (PRECISIONS) clinical trial","volume":"22","author":"Podolanczuk","year":"2022","journal-title":"BMC Pulm Med"},{"key":"2026012807100763000_13.1.e003763.10","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2020-216732"},{"key":"2026012807100763000_13.1.e003763.11","doi-asserted-by":"crossref","DOI":"10.1186\/1465-9921-14-S1-S2","article-title":"The revised ATS\/ERS\/JRS\/ALAT diagnostic criteria for idiopathic pulmonary fibrosis (IPF) - practical implications","volume":"14","author":"Wells","year":"2013","journal-title":"Respir Res"},{"key":"2026012807100763000_13.1.e003763.12","doi-asserted-by":"publisher","DOI":"10.1183\/20734735.012717"},{"key":"2026012807100763000_13.1.e003763.13","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.2111053"},{"key":"2026012807100763000_13.1.e003763.14","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-156-10-201205150-00004"},{"key":"2026012807100763000_13.1.e003763.15","unstructured":"Weir CB , Jan A . BMI classification percentile and cut off points.2023. Available: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK541070\/"},{"key":"2026012807100763000_13.1.e003763.16","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gku181","article-title":"Estimating telomere length from whole genome sequence data","volume":"42","author":"Ding","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"2026012807100763000_13.1.e003763.17","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/nature09298","article-title":"Integrating common and rare genetic variation in diverse human populations","volume":"467","author":"International HapMap","year":"2010","journal-title":"Nature New Biol"},{"key":"2026012807100763000_13.1.e003763.18","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01592-2016","article-title":"Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry","volume":"49","author":"Jo","year":"2017","journal-title":"Eur Respir J"},{"key":"2026012807100763000_13.1.e003763.19","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-019-1271-z","article-title":"The European MultiPartner IPF registry (EMPIRE): validating long-term prognostic factors in idiopathic pulmonary fibrosis","volume":"21","author":"Tran","year":"2020","journal-title":"Respir Res"},{"key":"2026012807100763000_13.1.e003763.20","doi-asserted-by":"crossref","DOI":"10.1186\/s12890-019-0986-4","article-title":"Baseline characteristics and comorbidities in the CAnadian REgistry for Pulmonary Fibrosis","volume":"19","author":"Fisher","year":"2019","journal-title":"BMC Pulm Med"},{"key":"2026012807100763000_13.1.e003763.21","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-019-1161-4","article-title":"Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat","volume":"20","author":"Maher","year":"2019","journal-title":"Respir Res"},{"key":"2026012807100763000_13.1.e003763.22","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S2213-2600(20)30036-9","article-title":"Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial","volume":"8","author":"Wells","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2026012807100763000_13.1.e003763.23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1013660"},{"key":"2026012807100763000_13.1.e003763.24","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1164\/rccm.202205-0845OC","article-title":"PCSK6 and Survival in Idiopathic Pulmonary Fibrosis","volume":"207","author":"Oldham","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012807100763000_13.1.e003763.25","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2213-2600(22)00251-X","article-title":"Longitudinal lung function and gas transfer in individuals with idiopathic pulmonary fibrosis: a genome-wide association study","volume":"11","author":"Allen","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2026012807100763000_13.1.e003763.26","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S2213-2600(20)30364-7","article-title":"Telomere length and risk of idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease: a mendelian randomisation study","volume":"9","author":"Duckworth","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2026012807100763000_13.1.e003763.27","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201809-1646OC"},{"key":"2026012807100763000_13.1.e003763.28","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S2213-2600(25)00045-1","article-title":"Rare variants and survival of patients with idiopathic pulmonary fibrosis: analysis of a multicentre, observational cohort study with independent validation","volume":"13","author":"Alonso-Gonz\u00e1lez","year":"2025","journal-title":"Lancet Respir Med"},{"key":"2026012807100763000_13.1.e003763.29","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S2213-2600(24)00147-4","article-title":"Cluster analysis of blood biomarkers to identify molecular patterns in pulmonary fibrosis: assessment of a multicentre, prospective, observational cohort with independent validation","volume":"12","author":"Fainberg","year":"2024","journal-title":"Lancet Respir Med"},{"key":"2026012807100763000_13.1.e003763.30","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202202-0399ST"},{"key":"2026012807100763000_13.1.e003763.31","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201905-1017OC"},{"key":"2026012807100763000_13.1.e003763.32","doi-asserted-by":"crossref","DOI":"10.1038\/s42003-021-01910-y","article-title":"Identification of a missense variant in SPDL1 associated with idiopathic pulmonary fibrosis","volume":"4","author":"Dhindsa","year":"2021","journal-title":"Commun Biol"},{"key":"2026012807100763000_13.1.e003763.33","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S2213-2600(17)30349-1","article-title":"Validation of a 52-gene risk profile for outcome prediction in patients with idiopathic pulmonary fibrosis: an international, multicentre, cohort study","volume":"5","author":"Herazo-Maya","year":"2017","journal-title":"Lancet Respir Med"},{"key":"2026012807100763000_13.1.e003763.34","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/S2213-2600(15)00048-X","article-title":"Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study","volume":"3","author":"Jenkins","year":"2015","journal-title":"Lancet Respir Med"},{"key":"2026012807100763000_13.1.e003763.35","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-019-1118-7","article-title":"Biomarkers of collagen synthesis predict progression in the PROFILE idiopathic pulmonary fibrosis cohort","volume":"20","author":"Organ","year":"2019","journal-title":"Respir Res"},{"key":"2026012807100763000_13.1.e003763.36","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S2213-2600(17)30430-7","article-title":"An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study","volume":"5","author":"Maher","year":"2017","journal-title":"Lancet Respir Med"},{"key":"2026012807100763000_13.1.e003763.37","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01181-2021"},{"key":"2026012807100763000_13.1.e003763.38","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1164\/rccm.202311-2185OC","article-title":"Deep Learning-based Segmentation of Computed Tomography Scans Predicts Disease Progression and Mortality in Idiopathic Pulmonary Fibrosis","volume":"210","author":"Thillai","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012807100763000_13.1.e003763.39","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1164\/rccm.201511-2152OC","article-title":"Daily Home Spirometry: An Effective Tool for Detecting Progression in Idiopathic Pulmonary Fibrosis","volume":"194","author":"Russell","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012807100763000_13.1.e003763.40","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201607-1408OC"},{"key":"2026012807100763000_13.1.e003763.41","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S2213-2600(19)30255-3","article-title":"Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study","volume":"7","author":"Maher","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2026012807100763000_13.1.e003763.42","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S2213-2600(19)30341-8","article-title":"Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"8","author":"Maher","year":"2020","journal-title":"Lancet Respir Med"}],"container-title":["BMJ Open Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjresp-2025-003763","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T15:10:17Z","timestamp":1769613017000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopenrespres.bmj.com\/lookup\/doi\/10.1136\/bmjresp-2025-003763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,28]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/bmjresp-2025-003763"],"URL":"https:\/\/doi.org\/10.1136\/bmjresp-2025-003763","relation":{},"ISSN":["2052-4439"],"issn-type":[{"value":"2052-4439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}